Analysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation

Summary

The goal of this observational study is to assess the performance of the multiFlux hemofilterwith regional or systemic anticoagulation during CKRT treatments. The multiFlux hemofilter is a single use device within the extracorporeal blood circuit during extracorporeal blood purification treatments for acute renal replacement therapies.

Conditions

• Acute Kidney Injury
• Renal Failure

Interventions

DEVICE

multiFlux 160 hemofilter with regional heparin anticoagulation

Extracorporeal blood purification with the multiFlux 160 hemofilter during continuous kidney replacement therapy with RCA systemic heparin anticoagulation for patients suffering from acute kidney injury (AKI)

DEVICE

multiFlux 160 hemofilter with RCA with regional citrate anticoagulation

Extracorporeal blood purification with the multiFlux 160 hemofilter during continuous kidney replacement therapy with RCA using 4% citrate with Ci-Ca dialysate (without gas barrier) for patients suffering from acute kidney injury (AKI)

DEVICE

multiFlux 130 hemofilter with regional heparin anticoagulation

Extracorporeal blood purification with the multiFlux 130 hemofilter during continuous kidney replacement therapy with RCA systemic heparin anticoagulation for patients suffering from acute kidney injury (AKI)

DEVICE

multiFlux 130 hemofilter with RCA with regional citrate anticoagulation

Extracorporeal blood purification with the multiFlux130 hemofilter during continuous kidney replacement therapy with RCA using 4% citrate with Ci-Ca dialysate (without gas barrier) for patients suffering from acute kidney injury (AKI)

DEVICE

multiFlux 60 hemofilter with regional heparin anticoagulation

Extracorporeal blood purification with the multiFlux 60 hemofilter during continuous kidney replacement therapy with RCA systemic heparin anticoagulation for patients suffering from acute kidney injury (AKI)

DEVICE

multiFlux 60 hemofilter with RCA with regional citrate anticoagulation

Extracorporeal blood purification with the multiFlux 60 hemofilter during continuous kidney replacement therapy with RCA using 4% citrate with Ci-Ca dialysate (without gas barrier) for patients suffering from acute kidney injury (AKI)

Sponsors & Collaborators

• Mediconomics GmbH

  collaborator UNKNOWN

• Fresenius Medical Care Deutschland GmbH

  lead INDUSTRY

Principal Investigators

• Christina Scharf-Janßen, PD Dr. med. · LMU University Hospital

Eligibility

Min Age

1 Year

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-07-31

Primary Completion

2027-06-30

Completion

2027-12-31

Countries

• Germany

Study Locations